Business Insider

AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM ...

LONDON, May 17, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment ...
WPRI 12

AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic ...

LONDON, Dec. 6, 2022 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment ...